Drug-induced torsades de pointes and implications for drug development. - Wikidata - awgldk - TriplyDB

Drug-induced torsades de pointes and implications for drug development.

Drug-induced torsades de pointes and implications for drug development.

http://www.wikidata.org/entity/Q34984908

about

The channelopathies: novel insights into molecular and genetic mechanisms of human disease Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development Towards a better understanding of QT interval variability Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes [Perioperative treatment of patients with long QT syndrome].Electrophysiological mechanisms of long and short QT syndromes.High-precision recording of the action potential in isolated cardiomyocytes using the near-infrared fluorescent dye di-4-ANBDQBS.Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation.Quality assessment of digital annotated ECG data from clinical trials by the FDA ECG Warehouse.Quantitative performance of E-Scribe warehouse in detecting quality issues with digital annotated ECG data from healthy subjects.The effect of moxifloxacin on QTc and implications for the design of thorough QT studies.Dog left ventricular midmyocardial myocytes for assessment of drug-induced delayed repolarization: short-term variability and proarrhythmic potential.QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel.hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.The effect of renal transplantation on ventricular repolarization in children with chronic renal failure.Genetics of acquired long QT syndrome.Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current.HERG1 channelopathies Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.Interaction Between Domperidone and Ketoconazole: Toward Prediction of Consequent QTc Prolongation Using Purely In Vitro Information.Drug-induced long QT syndrome Methods of assessment and clinical relevance of QT dynamics Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes.Modulation of transmural repolarization.Cellular basis of drug-induced torsades de pointes Retroinverso analogs of spadin display increased antidepressant effects Evaluating the Use of Linear Mixed-Effect Models for Inference of the Concentration-QTc Slope Estimate as a Surrogate for a Biological QTc Model.Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects.Concatenated hERG1 tetramers reveal stoichiometry of altered channel gating by RPR-260243 Modulation of the late sodium current by ATX-II and ranolazine affects the reverse use-dependence and proarrhythmic liability of IKr blockade.Quantification of repolarization reserve to understand interpatient variability in the response to proarrhythmic drugs: a computational analysis Seizure-related cardiac repolarization abnormalities are associated with ictal hypoxemia.The Link between Inactivation and High-Affinity Block of hERG1 Channels C-Linker Accounts for Differential Sensitivity of ERG1 and ERG2 K+ Channels to RPR260243-Induced Slow Deactivation.A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses.Combined pharmacological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes.Effect of ramosetron on QTc interval: a randomised controlled trial in patients undergoing off-pump coronary artery bypass surgery Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes.Pharmacogenomics and acquired long QT syndrome.

P2860

Q24532317-02CD497B-E40D-4A56-AC1B-F0F1CCEF3346 Q24646866-FE767967-7668-4AB7-AC61-B1F688FFE409 Q27001737-4AF4A5D5-42BC-4D00-9873-34FD09614F16 Q28534878-FE803D88-B4C2-4E02-A8B8-01AD09928C2D Q30202960-57531626-4240-4C85-AAD5-FF0EE71CFC5A Q30234942-D203BD64-43F0-4822-9133-D3670F51226C Q30497050-3A239309-B793-40C4-8B84-34F20A6B8462 Q31026162-4A4E076D-25BB-46DA-8EF7-AAB459A25BF6 Q31129877-2D6CF9E4-8D33-47D1-8692-6BF02BE99A26 Q31150161-2D0F0D63-F6E6-487E-BB37-C9BDD81E66E0 Q33411837-65C00EF1-4928-4E55-80B4-141B75B61F84 Q33661043-14D4599F-B4BD-4606-B8FC-77F86130F1E3 Q33835424-F8F196B3-F332-4FCD-A9C2-C00F4A53C117 Q33845924-56FEA961-BC07-485D-9CF5-0DAFE4375640 Q33872024-925EA782-2DF3-4A06-A8AD-7F7C74454D94 Q33905822-D042395A-D4CA-40EE-B50E-19144FC2B7B6 Q33911355-A2E1B099-F208-4055-9D1B-807AF1BC589E Q33915930-3B557EF0-9BDC-4BFA-8105-51B569CA1CBF Q34100661-A00623FE-D9D4-48B0-8289-6928E62FD237 Q34116212-D15DC5C7-BCEB-4EDD-BEDD-DAFD319DC380 Q34358104-2A291AF3-61E3-463B-99A8-EAE0CD027ECF Q34522084-37018130-E5F4-4AC3-8DAB-80E676CEA0CC Q34562134-B84F5396-34FF-4FBF-BFD7-0527D80A3235 Q34661917-CAF0675E-685B-47C0-8321-9980A28A37AE Q34786459-EFAFB853-16E6-49D9-905A-47F037750033 Q34996777-68897482-1739-4601-936D-4AA7A3691EC8 Q35110110-BE6736F5-184E-46CB-B222-2C0D94AA8BE9 Q35142403-9D050A60-372D-4D0E-B8F7-85836EECB13F Q35156395-15536D83-8B1B-4BAC-9B85-51E4DB902DA8 Q35216467-04A86000-93EE-4E3D-9187-F50E01E69903 Q35456738-8A30F9AD-7AE5-4B42-8406-6DEADEC3AA7A Q35473832-BAD6CD73-755B-4540-A7B2-C11362333449 Q35600385-D9D512E9-01C6-49B9-8FC7-AB94210D66C4 Q35745902-2CAF455E-0B08-417A-B140-81DD97C04D50 Q35783016-B81177FD-FD6E-4C98-8327-D4A771AF12B1 Q35827376-C4A07FEB-4412-430E-B932-B63807B7D872 Q36094299-2D6CD919-C1AF-4F90-9E33-7F2DBC2245BF Q36094344-98FC1DDA-E03D-46CB-A6B9-6119D5EFFDDD Q36173814-258F789F-0571-4581-AE9F-8DB72D6FE4C9 Q36192679-5436114A-5D81-4B98-A4A2-399F66EB8571

P2860

Drug-induced torsades de pointes and implications for drug development.

http://www.wikidata.org/entity/Q34984908

description

2004 nî lūn-bûn

@nan

2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Drug-induced torsades de pointes and implications for drug development.

@ast

Drug-induced torsades de pointes and implications for drug development.

@en

Drug-induced torsades de pointes and implications for drug development.

@nl

type

label

Drug-induced torsades de pointes and implications for drug development.

@ast

Drug-induced torsades de pointes and implications for drug development.

@en

Drug-induced torsades de pointes and implications for drug development.

@nl

prefLabel

Drug-induced torsades de pointes and implications for drug development.

@ast

Drug-induced torsades de pointes and implications for drug development.

@en

Drug-induced torsades de pointes and implications for drug development.

@nl

P1433

Q34984908-B61FBE19-646C-40C9-9FB7-573661067387

P1476

Q34984908-360AE1E3-7A65-4F79-9AC9-066861E04AE3

P2093

Q34984908-091F4C66-1BE9-4F98-9D00-EBDB02DD33FD

Q34984908-1725913D-A5F6-4ABF-8F5F-7035F27ABE15

Q34984908-30A5B9BE-8414-4A0E-80F2-188F209B776D

Q34984908-5DE96704-81E6-4A1B-A12D-8EA5A49F6437

Q34984908-5E0C40CF-8677-46F7-BC94-A49F677EB6D2

Q34984908-7678361F-0002-4382-ABC0-5A69E852AED0

Q34984908-AA338126-8EA6-46E0-8B12-09AA3FF08DA7

Q34984908-D1DD8FD8-8461-447F-ACCD-50773E41308B

Q34984908-D8FBC62C-FC2C-4241-83CC-066EE1EE4970

P2860

Q34984908-07213B9F-7027-4EE1-8FA0-71EE8BC86029

Q34984908-091860A0-1FF8-4066-BE5A-BA598D1F38C0

Q34984908-0C535DF4-2659-409E-958F-710647FF003C

Q34984908-0ECBD615-81C2-4F6E-8365-0F5794A1799D

Q34984908-10304A90-F8DE-4EA9-9599-EED14D994A64

Q34984908-144B258D-8DC5-4297-A40F-8A3347E3FE2D

Q34984908-14E46A2B-BAB4-4401-966F-5BBAF4F2001D

Q34984908-150F7972-A491-4CEC-9945-F4DE37D9C670

Q34984908-18094C39-3AE6-455C-AC62-08CCA040ACC0

Q34984908-1B78C940-949D-46A2-80B1-43500A7891C5

P304

Q34984908-50CE33A7-E682-4DE6-9564-4A9EEE752FC4

P31

Q34984908-79E3632F-21AE-4F70-ACC1-0239D929C2D0

P356

Q34984908-541E6524-69FC-485E-BABB-65585480D919

P433

Q34984908-5F64DBF1-DA1F-494F-8DF5-333DDB31746F

P478

Q34984908-A7F5B9D2-9033-4579-B92C-1476CAC25AC5

P50

Q34984908-1AA5F57F-A6E8-4302-90A9-698FD35BAEE7

Q34984908-3C252E78-C530-4198-AC68-FE5290BC8604

P577

Q34984908-622A9DCA-50A0-435A-BC22-16D4155FCBA1

P5875

Q34984908-86C63B1E-8A5A-4BB4-A292-0AF2DD5CB94E

P698

Q34984908-9AC690DC-BDF3-4B37-95EB-09C7D2E1BFD0

P932

Q34984908-6FEDD17B-21E2-4A14-9C3D-3C73F1F58247

P356

J.1540-8167.2004.03534.X

P1433

Journal of Cardiovascular Electrophysiology

P1476

Drug-induced torsades de pointes and implications for drug development

@en

P2093

Dan M Roden

http://www.w3.org/2001/XMLSchema#string

Independent Academic Task Force

http://www.w3.org/2001/XMLSchema#string

Jeremy N Ruskin

http://www.w3.org/2001/XMLSchema#string

Louis R Cantilena

http://www.w3.org/2001/XMLSchema#string

Marek Malik

http://www.w3.org/2001/XMLSchema#string

Michael Sanguinetti

http://www.w3.org/2001/XMLSchema#string

Raymond J Lipicky

http://www.w3.org/2001/XMLSchema#string

Robert R Fenichel

http://www.w3.org/2001/XMLSchema#string

Silvia G Priori

http://www.w3.org/2001/XMLSchema#string

P2860

MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia

Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death

A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?

Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole

A common polymorphism associated with antibiotic-induced cardiac arrhythmia

Modeling the heart--from genes to cells to the whole organ

A structural basis for drug-induced long QT syndrome

Differences in action potential and early afterdepolarization properties in LQT2 and LQT3 models of long QT syndrome

Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia

Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions

P304

475-495

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1540-8167.2004.03534.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Charles Antzelevitch

P577

2004-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227840885

http://www.w3.org/2001/XMLSchema#string

P698

15090000

http://www.w3.org/2001/XMLSchema#string

P932

1544371

http://www.w3.org/2001/XMLSchema#string